Trial Search Results

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol

The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID-19 but are not yet sick enough to require hospitalization. The overall hypothesis is that through an adaptive trial design, potential effective therapies (single and combination) may be identified for this group of patients.

COVID-19 Outpatient Pragmatic Platform Study (COPPS) is a pragmatic platform protocol designed to evaluate COVID-19 treatments by assessing their ability to reduce viral shedding (Viral Domain) or improve clinical outcomes (Clinical Domain). To be included into the platform, every investigational product will collect data for both Domain primary endpoints. Individual treatments to be evaluated in the platform will be described in separate sub-protocols.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Drug: Acebilustat
  • Drug: Placebo

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   1. Outpatient setting

   2. Age ≥ 18 years and ≤ 80 years at the time of the assessment

   3. Able and willing to understand the study, adhere to all study procedures, and provide
   written informed consent

   4. Initial diagnosis of COVID-19 disease as defined by an FDA-cleared molecular
   diagnostic assay positive for SARS-CoV-2 with no more than 72 hours from the initial
   swab used in the diagnosis to the time of commencing informed consent.

   5. At baseline, at least two symptoms should have mild or higher severity score, where at
   least one of the mild symptoms is not cough, fatigue, or loss of smell/taste OR at
   least one symptom has a moderate or higher severity score on the COVID Outpatient
   Symptom Scale (COSS).

   6. Participant's COVID-19 related symptom onset occurred within 7 days prior to time of
   randomization.

   7. Other inclusion criteria specific to the investigational product that may, in the eyes
   of the investigator, be deemed necessary.

Exclusion Criteria:

   1. At screening, the participant needs to be admitted to the hospital or is being
   evaluated for potential admission.

   2. Previous use of experimental drugs that may be active against COVID-19 in the eyes of
   the investigators.

   3. Participant yields a positive urine pregnancy test at screening.

   4. Participant is using adrenocorticosteroids (except topical or inhaled preparations or
   oral preparations equivalent to or less than 10 mg of oral prednisone) or
   immunosuppressive or immunomodulatory drugs (e.g., immunosuppressants, anticancer
   drugs, interleukins, interleukin antagonists or interleukin receptor blockers).

   NOTE: Treatment of study participants following institutional COVID-19 treatment
   policies or guidelines, including the use of immunomodulatory medications, is
   permitted. This excludes treatment with agents that have the potential for direct
   antiviral activity, including convalescent plasma and NO, and co-enrollment into other
   clinical studies that evaluate investigational agents for COVID-19.

   5. Participant has a serious chronic disease (e.g., uncontrolled human immunodeficiency
   virus [HIV], cancer requiring chemotherapy within the preceding 6 months, and/or
   moderate or severe hepatic insufficiency).

   6. Has renal insufficiency including severe renal impairment and ESRD and/or requiring
   hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).

   7. Has liver impairment greater than Child Pugh A.

   8. Has a history of alcohol or drug abuse in the previous 6 months.

   9. Has a psychiatric disease that is not well controlled where controlled is defined as:
   stable on a regimen for more than one year.

10. Has taken another investigational drug within the past 30 days.

11. Is deemed by the Investigator to be ineligible for any reason.

Additional exclusion criteria for acebilustat protocol:

   1. Patient has abnormal liver enzyme tests at screening, including AST or ALT ≥3 × the
   upper limit of normal (ULN) or total bilirubin >1.25 × ULN at Screening (patients with
   known Gilbert's syndrome can be included with bilirubin >1.25 × ULN).

   2. Patient is pregnant or breastfeeding.

   3. Patients with baseline ALT >1.5 × ULN.

Ages Eligible for Study

18 Years - 80 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting